April 2026 - BioMedWire (BMW)

ThursdayApr 30, 2026 10:00 am

House Hearing Puts Hospital CEOs on the Spot Over Exorbitant Charges

During a recent House hearing conducted by the Ways and Means Committee, hospital CEOs were put on the spot over the inexplicably high facility fees that they charge. GOP members of the committee accused the hospitals of taking advantage of the healthcare system and of overcharging patients. The hospital executives who attended the hearing included those from CommonSpirit Health, HCA Healthcare, ECU Health and New York Presbyterian. Approximately $1.6 trillion of the money spent on healthcare in 2024 went to hospitals, and this was approximately 33% of the total amount that went to healthcare in that year. The executives asserted that it was within their rights to levy higher fees when…

TuesdayApr 28, 2026 10:00 am

Study Finds Exercise, Ibuprofen Combat Brain Fog in Cancer Patients

Most cancer patients report cognitive deterioration, such as memory loss and difficulty concentrating as they undergo cancer treatments like chemotherapy and radiation. This has widely come to be known as “chemo brain.” Recent research suggests that exercising and taking a common OTC drug, ibuprofen, can alleviate these cognitive effects of cancer therapy. The study, which was conducted by a team at University of Rochester Medical Center, was led by Prof. Michelle Janelsins. The team recruited 86 patients undergoing cancer treatment and divided them into four groups during this Phase 2 clinical study. One group did exercises designed for cancer patients…

TuesdayApr 28, 2026 9:45 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Deploying AI for Non-Invasive Intoxication Detection

Voice Analytics and AI to Transform Drug and Alcohol Testing Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)and may include paid advertising. MindBio Therapeutics is developing AI-driven voice analysis technology to detect drug and alcohol impairment without relying on invasive and time-consuming breath, saliva, or laboratory testing. The company’s platform analyzes more than 140 acoustic markers and is trained on over 50 million data points to estimate intoxication levels from short voice samples. The new technology is seen applicable to both workplace and non-workplace settings, with the global alcohol and drug testing devices market projected to grow from…

TuesdayApr 28, 2026 9:00 am

The Evidence-Interrogation Play: How Oncotelic Therapeutics Inc.’s (OTLC) PDAOAI Platform Fits Pharma’s Broader AI Transformation

Oncotelic’s PDAOAI platform indexes 125,000+ PubMed abstracts on TGF-β signaling, enabling researchers to interrogate the evidence for testable, auditable hypotheses rather than rely on black-box predictions. Recent industry coverage places Oncotelic alongside Rockwell Automation, Emerson Electric, Thermo Fisher Scientific, and Danaher as contributors to the pharmaceutical sector’s shift toward AI-integrated operations. The hypothesis-first approach addresses a core challenge in biotech research: reducing training-set bias and building transparent, reproducible chains from question to evidence to hypothesis. Pharmaceutical research and manufacturing are undergoing a structural transition. Regulatory agencies are raising expectations around data integrity and traceability, while the industry is shifting from…

MondayApr 27, 2026 9:00 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Advancing AI Solutions for Cardiovascular Disease Detection and Management

The scale and impact of cardiovascular disease underscore why innovation in this area is so critical. Advances in genomics and epigenetics are making it possible to better understand how genetic predisposition and environmental influences interact to drive disease progression. By utilizing a simple blood test, Cardio Diagnostics is lowering barriers to advanced cardiovascular testing. Cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies. Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on addressing this need by developing advanced solutions that leverage artificial intelligence (“AI”) and multi-omic…

FridayApr 24, 2026 11:00 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) AI Platform Brings Precision to Heart Health

At the core of Cardio Diagnostics’ approach is the use of artificial intelligence to integrate multi-omic data to provide a more comprehensive view of cardiovascular health. The company’s proprietary platform is designed to analyze a patient’s molecular profile from a single blood draw and generate actionable insights related to cardiovascular disease risk. CDIO’s focus on accessibility and scalability is also notable. Cardiovascular diagnostics are undergoing a transformation as advances in molecular science and artificial intelligence (“AI”) converge to deliver more precise, individualized insights from minimally invasive tests. Cardio Diagnostics Holdings (NASDAQ: CDIO) is at the forefront of this shift, developing a proprietary…

FridayApr 24, 2026 10:00 am

Survey Finds That American Adults Want Health Inequities Eliminated

Last fall, Johns Hopkins School of Nursing through its Institute for Policy Solutions conducted a survey on health inequities and the full report from that survey was released weeks ago. The findings of that poll offer valuable insights that policymakers and all stakeholders need to weigh while making decisions impacting the health of Americans. The majority (70%) of the respondents say health care is a right and that it shouldn’t be treated as a privilege. The survey found that while there is a sense that Americans are heavily polarized on national issues, this isn’t the case when it comes to matters of health care. Notably, 62% of those who participated in the survey revealed…

ThursdayApr 23, 2026 10:00 am

New Urine Test Could Predict Response to Bladder Cancer Treatment

Researchers have developed a urine test that can screen for tumor DNA and detect whether a patient has residual bladder cancer after they have undergone surgery to remove the tumor. This test may also detect whether immunotherapy treatment administered after surgery has been effective or residual bladder cancer remains. The study containing those findings appeared in the journal Cell. If this urine test is successfully validated in larger clinical trials, it could mark a major shift in the way bladder cancer is treated. Conventionally, bladder cancer is monitored by obtaining a tissue sample for molecular analysis. This approach is costly and subjects patients to several invasive procedures. With this new test, all a…

WednesdayApr 22, 2026 9:00 am

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

BioMedWire Editorial Coverage: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is supported by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to incorporate clinical progress, probability of success and expected commercialization timelines into measurable balance sheet value. Companies at the…

TuesdayApr 21, 2026 10:00 am

Why Molecular Testing is Increasingly Important in CNS Cancers

Primary and metastatic central nervous system (CNS) tumors can have extraordinary biological and anatomical complexity, and these tumors can be hard to identify using traditional imaging or histopathology analysis. Molecular analysis has emerged as a major way to identify these tumors and help medical teams plan how best to help those diagnosed with these cancers. Biomarker testing is a growing field that is making it possible for the molecular structure of CNS cancers to be analyzed for not only diagnostic purposes but also other functions as well. Recent advances like the detection of tumor RNA particles in blood samples now mean that a brain cancer can be identified and tracked without subjecting patients to…